Teachers Advisors LLC grew its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 135.9% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 995,930 shares of the biopharmaceutical company’s stock after buying an additional 573,663 shares during the quarter. Teachers Advisors LLC owned 0.45% of Alexion Pharmaceuticals worth $121,175,000 as of its most recent SEC filing.
Other large investors have also recently modified their holdings of the company. Guardian Life Insurance Co. of America raised its position in shares of Alexion Pharmaceuticals by 0.7% in the 1st quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 6 shares in the last quarter. Meeder Asset Management Inc. acquired a new position in shares of Alexion Pharmaceuticals in the 1st quarter valued at approximately $111,000. Fiduciary Trust Co. acquired a new position in shares of Alexion Pharmaceuticals in the 2nd quarter valued at approximately $111,000. Huntington National Bank raised its position in shares of Alexion Pharmaceuticals by 1,084.6% in the 2nd quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 987 shares in the last quarter. Finally, Penserra Capital Management LLC raised its position in shares of Alexion Pharmaceuticals by 13.0% in the 2nd quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 144 shares in the last quarter. Institutional investors own 94.26% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Teachers Advisors LLC Has $121.18 Million Stake in Alexion Pharmaceuticals, Inc. (ALXN)” was first published by Zolmax and is owned by of Zolmax. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://zolmax.com/investing/teachers-advisors-llc-has-121-18-million-stake-in-alexion-pharmaceuticals-inc-alxn/1639885.html.
This article was originally published by and is the sole property of Zolmax. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://zolmax.com/investing/teachers-advisors-llc-has-121-18-million-stake-in-alexion-pharmaceuticals-inc-alxn/1639885.html
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) traded up 0.0393% during midday trading on Wednesday, hitting $144.1267. 265,723 shares of the stock were exchanged. The company’s 50 day moving average is $137.20 and its 200-day moving average is $124.25. Alexion Pharmaceuticals, Inc. has a 1-year low of $96.18 and a 1-year high of $149.34. The stock has a market cap of $32.17 billion, a PE ratio of 62.5007 and a beta of 1.40.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, topping the consensus estimate of $1.08 by $0.48. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The company had revenue of $912.00 million for the quarter, compared to the consensus estimate of $846.15 million. During the same period in the previous year, the firm earned $1.13 earnings per share. The firm’s revenue for the quarter was up 21.1% on a year-over-year basis. On average, analysts expect that Alexion Pharmaceuticals, Inc. will post $5.61 earnings per share for the current year.
ALXN has been the subject of several analyst reports. Morgan Stanley upgraded shares of Alexion Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $101.08 to $138.00 in a research report on Thursday, May 25th. Cowen and Company reiterated an “outperform” rating and set a $122.00 price objective on shares of Alexion Pharmaceuticals in a research report on Monday, July 3rd. J P Morgan Chase & Co cut shares of Alexion Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research report on Tuesday, May 23rd. SunTrust Banks, Inc. reiterated a “buy” rating and set a $165.00 price objective on shares of Alexion Pharmaceuticals in a research report on Friday, July 14th. Finally, Leerink Swann reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Tuesday, May 23rd. Five equities research analysts have rated the stock with a hold rating, twenty have given a buy rating and three have assigned a strong buy rating to the company. Alexion Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $157.55.
In related news, Director Bros. Advisors Lp Baker purchased 660,779 shares of the business’s stock in a transaction that occurred on Thursday, June 15th. The shares were acquired at an average price of $117.33 per share, for a total transaction of $77,529,200.07. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ann M. Veneman sold 700 shares of Alexion Pharmaceuticals stock in a transaction on Monday, July 31st. The shares were sold at an average price of $137.74, for a total transaction of $96,418.00. Following the completion of the sale, the director now owns 6,315 shares in the company, valued at approximately $869,828.10. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 17,070 shares of company stock worth $2,416,869. 4.35% of the stock is owned by insiders.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.